Takeda Pharmaceutical Co Stock Current Asset
| TAK Stock | USD 13.62 0.05 0.37% |
Takeda Pharmaceutical Co fundamentals help investors to digest information that contributes to Takeda Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Takeda Stock. The fundamental analysis module provides a way to measure Takeda Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Takeda Pharmaceutical stock.
At this time, Takeda Pharmaceutical's Non Current Assets Total are quite stable compared to the past year. Other Current Assets is expected to rise to about 292.4 B this year, although the value of Total Current Assets will most likely fall to about 2 T. Takeda | Current Asset |
Takeda Pharmaceutical Co Company Current Asset Analysis
Takeda Pharmaceutical's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Takeda Current Asset Historical Pattern
Today, most investors in Takeda Pharmaceutical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Takeda Pharmaceutical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Takeda Pharmaceutical current asset as a starting point in their analysis.
Takeda Pharmaceutical Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Takeda Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Takeda Pharmaceutical Co has a Current Asset of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Takeda Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Takeda Pharmaceutical's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Takeda Pharmaceutical could also be used in its relative valuation, which is a method of valuing Takeda Pharmaceutical by comparing valuation metrics of similar companies.Takeda Pharmaceutical is currently under evaluation in current asset category among its peers.
Takeda Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Takeda Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Takeda Pharmaceutical's managers, analysts, and investors.Environmental | Governance | Social |
Takeda Fundamentals
| Return On Equity | 0.0415 | ||||
| Return On Asset | 0.0278 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 70.22 B | ||||
| Shares Outstanding | 3.17 B | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 2.40 % | ||||
| Number Of Shares Shorted | 5.66 M | ||||
| Price To Earning | 27.57 X | ||||
| Price To Book | 0.94 X | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 4.26 T | ||||
| Gross Profit | 2.44 T | ||||
| EBITDA | 900.33 B | ||||
| Net Income | 144.07 B | ||||
| Cash And Equivalents | 533.53 B | ||||
| Cash Per Share | 208.91 X | ||||
| Total Debt | 5.46 T | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 1.18 X | ||||
| Book Value Per Share | 4,366 X | ||||
| Cash Flow From Operations | 716.34 B | ||||
| Short Ratio | 3.88 X | ||||
| Earnings Per Share | 0.60 X | ||||
| Price To Earnings To Growth | 0.70 X | ||||
| Target Price | 2471.44 | ||||
| Number Of Employees | 49.28 K | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 43.18 B | ||||
| Total Asset | 15.11 T | ||||
| Retained Earnings | 1.39 T | ||||
| Working Capital | 245.48 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 4.54 % | ||||
| Net Asset | 15.11 T | ||||
| Last Dividend Paid | 192.0 |
About Takeda Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Takeda Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takeda Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takeda Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Takeda Pharmaceutical Piotroski F Score and Takeda Pharmaceutical Altman Z Score analysis. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.049 | Dividend Share 192 | Earnings Share 0.6 | Revenue Per Share 1.4 K | Quarterly Revenue Growth 0.127 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.